DDInter648 DDInter782
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Disopyramide
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Entrectinib may lead to a major life threatening interaction when taken with Disopyramide
Entrectinib may lead to a major life threatening interaction when taken with Macimorelin